'Psyched': MindMed Acquires Rights For LSD Research, NewLeaf Brands To Purchase Mushroom Company

Psyched is a bi-monthly column covering the most important developments in the industry of medicinal psychedelics. We hope you follow us periodically as we report on the growth of this exciting new industry.

Versión en Español en El Planteo.

MindMed Inks Deal With Switzerland University For Rights On LSD Research

Neuro-pharmaceutical and psychedelics company Mind Medicine Inc. MMED has acquired exclusive rights to data, compounds, and patents for research with LSD and other psychedelics from the Liechti laboratory in Switzerland’s University Hospital Basel. The company released an announcement on April 1.

"Over the past decade we have amassed the largest collection of clinical trials around LSD," said Matthias Liechti, who heads the psychedelics research lab at University Hospital Basel. 

MindMed has a special interest in a Phase 2 clinical trial on high-dose LSD treatment for anxiety currently being conducted by Liechti’s lab. The company will also work under the direction of Dr. Liechti to continue developing therapy with LSD micro-dose as a potential treatment for adult ADHD.

Through future commercial clinical drug trials, the goal is to turn LSD into an FDA approved medicine as a way to treat mental illnesses.

NewLeaf Brands Signs LOI to Purchase Mushroom Company

CBD and lifestyle company NewLeaf Brands NLB NLBIF signed a letter of intent dated April 6 to acquire Mydecine Group.

Mydecine is a Colorado-based company that aims to become a leader in cultivation, processing, and R&D for psychoactive mushrooms and its derivative products.

While psilocybin, the active compound found in “magic” mushrooms was decriminalized in Denver last year, sale is still illegal and punishable by law.

NewLeaf has committed to the purchase of 100% of Mydecine shares for the sum of $850,000, to be paid in NewLeaf shares.

“Given that we are located in the home state to first decriminalize psilocybin in the U.S., the Company has had a unique opportunity to get a jump on the potential industry as a whole,” said Joshua Bartch, CEO of NewLeaf Brands. “We share a common vision of Mydecine in the sense of seeing the vast potential of mycology [mushroom science] as a whole, not just the compound psilocybin.”

MicroDose Psychedelics Conference To Be Held Online on April 14-15

MicroDose.Buzz and The Conscious Fund will hold a Virtual Conference on Psychedelic Medicine.

The event features almost 100 speakers including Dennis McKenna, along with CEOs, investors, scientists, researchers and regulators like Robin Carhart-Harris, Ronan Levy, and Paul Austin.

The conference begins on Tuesday at 12 p.m. EST and continues into Wednesday. Tickets can be purchased at Eventbrite, starting at $40

Cover picture based on photo from Unsplash

Posted In: Joshua BartchLSDMatthias LiechtiMicroDose.BuzzMind Medicine Inc.NewLeaf BrandsPsilocybinpsychedelicsThe Conscious FundCannabisMarkets

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.